The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis
Open accessAbstract
Repeat cycles of miridesap, to deplete circulating serum amyloid P component (SAP), followed by the anti-SAP antibody, dezamizumab, cleared visceral amyloid deposits in patients with systemic amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Our data demonstrated that CPHPC (miridesap), developed by Pepys’ team at University College London90–92, efficiently reduces SAP concentration in serum (58.5% reduction) and bone marrow (95% reduction) in aged mice.”
From Serum amyloid P secreted by bone marrow adipocytes drives skeletal amyloidosis (2025) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moon, J., Messroghli, D., Kellman, P., Piechnik, S. K., Robson, M. D., Ugander, M., Gatehouse, P. D., Arai, A. E., Friedrich, M. G., Neubauer, S., et al. (2013) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-15-92 · Cited by 1,140
Self-citationComplement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J. M., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 797
Pepys, M. B. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131243 · Cited by 566
Self-citationTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Self-citationTherapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
Richards, D. B., Cookson, L., Berges, A., Barton, S. V., Lane, T., Ritter, J., Fontana, M., Moon, J., Pinzani, M., Gillmore, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504942 · Cited by 342
Self-citationQuantification of Myocardial Extracellular Volume Fraction in Systemic AL Amyloidosis
Banypersad, S. M., Sado, D. M., Flett, A. S., et al. (2012) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.112.978627 · Cited by 337
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Bodin, K., Ellmerich, S., Kahan, M., Tennent, G. A., Loesch, A., Gilbertson, J. A., Hutchinson, W. L., Mangione, P. P., Gallimore, J. R., Millar, D. J., et al. (2010) · Nature · doi:10.1038/nature09494 · Cited by 336
Self-citationHuman plasma fibrinogen is synthesized in the liver
Tennent, G. A., Brennan, S. O., Stangou, A. J., O'Grady, J., Hawkins, P. N., & Pepys, M. B. (2007) · Blood · doi:10.1182/blood-2006-08-040956 · Cited by 304
Self-citationAmyloid P component. A critical review
Pepys, M. B., Booth, D. R., Hutchinson, W. L., Gallimore, J. R., Collins, I. M., & Hohenester, E. (1997) · Amyloid · doi:10.3109/13506129709003838 · Cited by 181 · cited 1×
“Human serum amyloid P component (SAP) from the plasma is present in all human amyloid deposits due to its avid but reversible bind ing to amyloid fibrils of all types (4).”
BackgroundSelf-citationMilde, R., Ritter, J. M., Tennent, G. A., Loesch, A., Martínez, F. O., Gordon, S., Pepys, M. B., Verschoor, A., & Helming, L. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.065 · Cited by 162
Self-citationGillmore, J., Tennent, G., Hutchinson, W., Gallimore, J., Lachmann, H., Goodman, H., Offer, M., Millar, D., Petrie, A., Hawkins, P., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08036.x · Cited by 136
Self-citationLovat, L. B., Persey, M. R., Madhoo, S., et al. (1998) · Gut · doi:10.1136/gut.42.5.727 · Cited by 133
Liver AL amyloidosis as a possible cause of high liver stiffness values
Lanzi, A., Gianstefani, A., Mirarchi, M. G., et al. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283309d5b · Cited by 43
Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis
Sahota, T., Berges, A., Barton, S., Cookson, L., Zamuner, S., & Richards, D. (2015) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.15 · Cited by 19 · cited 3×
“The miridesap dose of 60 mg, three times a day, was adjusted for renal impairment, if necessary, to keep predicted exposure below preestablished protocoldefined safety limits (8).”
BackgroundMethodResultSelf-citationHawkins, P. N., Richardson, S., Vigushin, D. M., David, J., Kelsey, C. R., Gray, R. E. S., Hall, M. A., Woo, P., Lavender, J. P., & Pepys, M. B. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360616
Self-citationHawkins, P. N. (1994) · Clinical Science · doi:10.1042/cs0870289
Self-citationImaging amyloidosis with radiolabelled SAP
Hawkins, P. N., & Pepys, M. B. (1995) · European Journal of Nuclear Medicine · doi:10.1007/bf01254559
Self-citationEdwards, C. V., Gould, J., Langer, A. L., Mapara, M., Radhakrishnan, J., Maurer, M. S., Raza, S., Mears, J. G., Wall, J. S., Solomon, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.643.643
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
Wall, J. S., Kennel, S. J., Stuckey, A. C., Long, M. J., Townsend, D. W., Smith, G. T., Wells, K. J., Fu, Y., Stabin, M. G., Weiss, D. T., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273797
Bandula, S., Banypersad, S. M., Sado, D., Flett, A. S., Punwani, S., Taylor, S. A., Hawkins, P. N., & Moon, J. C. (2013) · Radiology · doi:10.1148/radiol.13121889
Self-citation
Research works printed but not linked: 5
- M. A. Gertz, H. J. Landau, B. M. Weiss, Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody. Am. J. Hematol. 91, E506–E508 (2016). · DOI
- V. Loustaud-Ratti, A. Cypierre, A. Rousseau, F. Yagoubi, J. Abraham, A.-L. Fauchais, P. Carrier, A. Lefebvre, D. Bordessoule, E. Vidal, D. Sautereau, A. Jaccard, Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 18, 19–24 (2011). · DOI
- P. N. Hawkins, J. P. Lavender, M. B. Pepys, Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N. Engl. J. Med. 323, 508–513 (1990). · DOI
- D. F. Hutt, T. Lane, J. D. Gillmore, H. J. Lachmann, S. D. J. Gibbs, P. T. Sattianayagam, D. Gopaul, A. M. Quigley, P. N. Hawkins, A. D. Wechalekar, Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis. Amyloid 17 (suppl. 1), 57 (2010).
- D. F. Hutt, A.-M. Quigley, J. Page, M. L. Hall, M. Burniston, D. Gopaul, T. Lane, C. J. Whelan, H. J. Lachmann, J. D. Gillmore, P. N. Hawkins, A. D. Wechalekar, Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur. Heart J. Cardiovasc. Imaging 15, 1289–1298 (2014). · DOI
Cited by
Sorted by citations
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A. A., Sanchorawala, V., Schönland, S. O., Palladini, G. O., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 557
Self-citationTransthyretin Cardiac Amyloidosis: An Update on Diagnosis and Treatment
Yamamoto, H., & Yokochi, T. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12518 · Cited by 198
Treatment of cardiac transthyretin amyloidosis: an update
Emdin, M., Aimo, A., Rapezzi, C., Fontana, M., Perfetto, F., Seferovic, P. M., Barison, A., Castiglione, V., Vergaro, G., Giannoni, A., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz298 · Cited by 155
Self-citationPapa, R., & Lachmann, H. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.06.004 · Cited by 139
Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment
Gertz, M. A. (2018) · American journal of hematology/oncology · doi:10.1002/ajh.25149 · Cited by 130
“ing with SAP scans and decreased liver stiffness as measured with the use of elastography NCT01777243.(152,153) An antibody to a cryptic”
Method
Metadata
- Authors
- Richards, D. B., Cookson, L. M., Barton, S. V., Liefaard, L., Lane, T., Hutt, D. F., Ritter, J. M., Fontana, M., Moon, J. C., Gillmore, J. D., Wechalekar, A., Hawkins, P. N., & Pepys, M. B.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- National Health Service (GB)
- Guy's Hospital (GB)
- St Bartholomew's Hospital (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-01-03
- Volume
- 10
- Issue
- 422
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2782423765
- Cited by
- 136
- References
- 0
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 18 · 2023: 8 · 2022: 21 · 2021: 20 · 2020: 20 · 2019: 20 · 2018: 13
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- GlaxoSmithKline (award308029, N/A)
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- systemic amyloidosis, cardiac amyloidosis, serum amyloid P component, anti-amyloid antibodies, amyloid deposition, spleen, kidney, antibody therapy
- MeSH terms
- Serum Amyloid P-Component, Amyloidosis, Antibodies, Humans, Magnetic Resonance Imaging, Radionuclide Imaging, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
